Sheena Jonathan, a co-founder of Natera, Inc., has reported the sale of 2,930 shares of the company's stock on October 21, 2026. This transaction is significant as it highlights ongoing trading activity by key stakeholders within the medical laboratory services sector.
Natera, Inc. specializes in medical laboratory services, focusing on genetic testing and related technologies. The company is incorporated in Delaware and has its headquarters in Austin, Texas. Its recent filings indicate a series of stock transactions, with Jonathan being an active participant.
According to the latest filing, Jonathan sold shares at various prices ranging from $406.50 to $416.67 per share. The total number of shares sold in this transaction was 2,930, which included multiple transactions executed on the same day. Following these transactions, Jonathan retains ownership of 218,164 shares of Natera, Inc.
The filing, accession number 0001646649-26-000035, indicates that these sales were made under a Rule 10b5-1 trading plan established on December 12, 2025. This type of plan allows company insiders to set up a predetermined schedule for selling shares, which helps to avoid any potential accusations of insider trading.
This activity may affect Natera's market perception, as stakeholders and investors analyze the motivations behind such sales. In the competitive landscape of medical laboratories, other companies will be watching closely to gauge how this might influence their own stock performance and strategic decisions.
Looking ahead, the filing does not specify what actions may follow this recent sale of shares by Jonathan. Investors and analysts will likely be attentive to any further disclosures from Natera, especially regarding the implications of these transactions on the company's future direction.